000255687 001__ 255687
000255687 005__ 20220930130047.0
000255687 0247_ $$2doi$$a10.1093/neuonc/nov088
000255687 0247_ $$2ISSN$$a1522-8517
000255687 0247_ $$2ISSN$$a1523-5866
000255687 0247_ $$2WOS$$aWOS:000361306400015
000255687 0247_ $$2altmetric$$aaltmetric:4057332
000255687 0247_ $$2pmid$$apmid:26008606
000255687 037__ $$aFZJ-2015-05820
000255687 041__ $$aEnglish
000255687 082__ $$a610
000255687 1001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b0$$eCorresponding author
000255687 245__ $$aThe use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma
000255687 260__ $$aOxford$$bOxford Univ. Press$$c2015
000255687 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1443094779_332
000255687 3367_ $$2DataCite$$aOutput Types/Journal article
000255687 3367_ $$00$$2EndNote$$aJournal Article
000255687 3367_ $$2BibTeX$$aARTICLE
000255687 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000255687 3367_ $$2DRIVER$$aarticle
000255687 520__ $$aBackground We evaluated the diagnostic value of static and dynamic O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) PET parameters in patients with progressive or recurrent glioma.Methods We retrospectively analyzed 132 dynamic 18F-FET PET and conventional MRI scans of 124 glioma patients (primary World Health Organization grade II, n = 55; grade III, n = 19; grade IV, n = 50; mean age, 52 ± 14 y). Patients had been referred for PET assessment with clinical signs and/or MRI findings suggestive of tumor progression or recurrence based on Response Assessment in Neuro-Oncology criteria. Maximum and mean tumor/brain ratios of 18F-FET uptake were determined (20–40 min post-injection) as well as tracer uptake kinetics (ie, time to peak and patterns of the time–activity curves). Diagnoses were confirmed histologically (95%) or by clinical follow-up (5%). Diagnostic accuracies of PET and MR parameters for the detection of tumor progression or recurrence were evaluated by receiver operating characteristic analyses/chi-square test.Results Tumor progression or recurrence could be diagnosed in 121 of 132 cases (92%). MRI and 18F-FET PET findings were concordant in 84% and discordant in 16%. Compared with the diagnostic accuracy of conventional MRI to diagnose tumor progression or recurrence (85%), a higher accuracy (93%) was achieved by 18F-FET PET when a mean tumor/brain ratio ≥2.0 or time to peak <45 min was present (sensitivity, 93%; specificity, 100%; accuracy, 93%; positive predictive value, 100%; P < .001).Conclusion Static and dynamic 18F-FET PET parameters differentiate progressive or recurrent glioma from treatment-related nonneoplastic changes with higher accuracy than conventional MRI.
000255687 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000255687 588__ $$aDataset connected to CrossRef
000255687 7001_ $$0P:(DE-Juel1)131627$$aStoffels, G.$$b1
000255687 7001_ $$0P:(DE-Juel1)141877$$aFilss, C.$$b2
000255687 7001_ $$0P:(DE-HGF)0$$aRapp, M.$$b3
000255687 7001_ $$0P:(DE-HGF)0$$aBlau, T.$$b4
000255687 7001_ $$0P:(DE-HGF)0$$aTscherpel, C.$$b5
000255687 7001_ $$0P:(DE-HGF)0$$aCeccon, G.$$b6
000255687 7001_ $$0P:(DE-Juel1)156211$$aDunkl, V.$$b7
000255687 7001_ $$0P:(DE-HGF)0$$aWeinzierl, M.$$b8
000255687 7001_ $$0P:(DE-HGF)0$$aStoffel, M.$$b9
000255687 7001_ $$0P:(DE-Juel1)165921$$aSabel, M.$$b10
000255687 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b11
000255687 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b12
000255687 7001_ $$0P:(DE-Juel1)131777$$aLangen, K.-J.$$b13
000255687 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nov088$$gp. nov088$$n9$$p1293-1300$$tNeuro-Oncology$$v17$$x1523-5866$$y2015
000255687 8564_ $$uhttps://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.pdf$$yRestricted
000255687 8564_ $$uhttps://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.gif?subformat=icon$$xicon$$yRestricted
000255687 8564_ $$uhttps://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000255687 8564_ $$uhttps://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.jpg?subformat=icon-180$$xicon-180$$yRestricted
000255687 8564_ $$uhttps://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.jpg?subformat=icon-640$$xicon-640$$yRestricted
000255687 8564_ $$uhttps://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.pdf?subformat=pdfa$$xpdfa$$yRestricted
000255687 8767_ $$92015-05-27$$d2015-05-28$$eColour charges$$jZahlung erfolgt
000255687 909CO $$ooai:juser.fz-juelich.de:255687$$pOpenAPC$$pVDB$$popenCost
000255687 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich GmbH$$b0$$kFZJ
000255687 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich GmbH$$b1$$kFZJ
000255687 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)141877$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000255687 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich GmbH$$b11$$kFZJ
000255687 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich GmbH$$b12$$kFZJ
000255687 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich GmbH$$b13$$kFZJ
000255687 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000255687 9141_ $$y2015
000255687 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000255687 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000255687 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2014
000255687 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000255687 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000255687 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000255687 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000255687 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000255687 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000255687 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000255687 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2014
000255687 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000255687 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000255687 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x2
000255687 980__ $$ajournal
000255687 980__ $$aVDB
000255687 980__ $$aI:(DE-Juel1)INM-3-20090406
000255687 980__ $$aI:(DE-Juel1)INM-4-20090406
000255687 980__ $$aI:(DE-82)080010_20140620
000255687 980__ $$aUNRESTRICTED
000255687 980__ $$aAPC
000255687 981__ $$aI:(DE-Juel1)INM-4-20090406